ADVFN US – Market Content Editor
-
U.S. Stock Futures Drop Amid New Tariffs, Amazon Miss; Eyes on Jobs Report
U.S. stock futures declined Friday evening as investors weighed the impact of newly announced tariffs from former President Donald Trump, disappointing earnings from Amazon, and awaited key labor market data. As of 05:55 ET, Dow Jones futures were down 375 points (-0.9%), S&P 500 futures lost 55 points (-0.9%), and Nasdaq 100 futures slipped 218…
-
U.S. Stocks Give Back Ground As Early Buying Interest Evaporates
After moving sharply higher early in the session, stocks gave back ground over the course of the trading day on Thursday. The major averages pulled back well off their best levels of the day and into negative territory. The major averages finished the day just off their lows of the session. The Nasdaq edged down…
-
Stock Market Today: S&P 500 Slips After Touching Record Highs Despite Microsoft, Meta Surge
The S&P 500 closed slightly lower Thursday after briefly hitting a new intraday high, as strong earnings from Microsoft and Meta Platforms failed to offset broader market weakness. At 3:08 p.m. ET, the Dow Jones Industrial Average dropped 330 points, or 0.7%. The S&P 500 slipped 0.01% after reaching a record 6,427.02 earlier in the…
-
Lilly shares slide as Mounjaro fails to outperform Trulicity in heart health study
Shares of Eli Lilly and Company (NYSE:LLY) dropped Thursday morning after the company announced that its diabetes treatment Mounjaro did not demonstrate superiority over Trulicity, its older GLP-1 medication, in a major cardiovascular trial. Following the release of topline findings from the SURPASS-CVOT study, which compared both treatments in adults with type 2 diabetes and…
-
Upbound Group Tops Q2 Estimates, Driven by Acima and Brigit Momentum
Upbound Group, Inc. (NASDAQ:UPBD) reported second-quarter results on Thursday that exceeded Wall Street expectations, thanks to robust growth in its Acima and Brigit segments. Shares inched up 0.04% in pre-market trading following the earnings release. The company posted adjusted earnings per share of $1.12, surpassing analyst estimates by $0.07, while revenue totaled $1.16 billion, above…
-
Stagwell Tops Q2 Revenue Forecasts, Stock Nudges Higher
Stagwell Inc. (NASDAQ:STGW) beat revenue expectations in the second quarter, supported by robust gains in its digital transformation business and market share growth. Following the announcement, shares inched up 0.19% in after-hours trading. The marketing services company reported adjusted earnings per share of $0.17, in line with analyst forecasts. Revenue came in at $707 million,…
-
S&P Global Tops Q2 Estimates on Strong Market Intelligence, Index Business
S&P Global Inc. (NYSE:SPGI) posted stronger-than-expected results for the second quarter, supported by robust performances in its Market Intelligence and S&P Dow Jones Indices units. The company’s shares moved up 1.07% in pre-market trading after the release. The financial data and analytics firm reported adjusted earnings per share of $4.43, well ahead of analysts’ expectations…
-
Terex Tops Q2 Expectations, Holds 2025 Guidance Amid Uneven Segment Results
Terex Corporation (NYSE:TEX) delivered stronger-than-expected earnings for the second quarter, buoyed by a solid showing in its Environmental Solutions division, even as other business units faced headwinds. Shares rose modestly by 0.44% in pre-market trading after the results were announced. The company reported adjusted earnings of $1.49 per share, outpacing the consensus estimate of $1.45.…
-
Kirby Corp. Edges Past Q2 Estimates; Shares Tick Slightly Higher
Kirby Corporation (NYSE:KEX) delivered second-quarter results that came in just ahead of Wall Street expectations, buoyed by steady performance across its marine transportation and distribution segments. Following the earnings release, shares inched up 0.01% in after-hours trading. The Houston-based barge transportation company reported earnings of $1.67 per share, narrowly beating the consensus estimate of $1.66.…
-
Psyence Biomedical Shares Soar 70% Following Partner’s Ibogaine Extraction Breakthrough
Psyence Biomedical Ltd. (NASDAQ:PBM) saw its stock skyrocket by 70% after announcing a major scientific milestone achieved by its strategic partner, PsyLabs. The partner successfully produced a GMP-compliant Ibogaine Total Alkaloid extract, marking a breakthrough in the scalable manufacturing of purified psychedelic compounds. The extract passed all required microbial safety standards for food-grade use, confirmed…